CA2873259C - Conjugate of a photosensitiser and chitosan and uses thereof - Google Patents

Conjugate of a photosensitiser and chitosan and uses thereof Download PDF

Info

Publication number
CA2873259C
CA2873259C CA2873259A CA2873259A CA2873259C CA 2873259 C CA2873259 C CA 2873259C CA 2873259 A CA2873259 A CA 2873259A CA 2873259 A CA2873259 A CA 2873259A CA 2873259 C CA2873259 C CA 2873259C
Authority
CA
Canada
Prior art keywords
compound
molecule
cells
composition
internalized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2873259A
Other languages
English (en)
French (fr)
Other versions
CA2873259A1 (en
Inventor
Kristian Berg
Anders Hogset
Mar Masson
Vivek S. GAWARE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PCI Biotech AS
Original Assignee
PCI Biotech AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PCI Biotech AS filed Critical PCI Biotech AS
Publication of CA2873259A1 publication Critical patent/CA2873259A1/en
Application granted granted Critical
Publication of CA2873259C publication Critical patent/CA2873259C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/00272-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/722Chitin, chitosan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2873259A 2012-05-15 2013-05-14 Conjugate of a photosensitiser and chitosan and uses thereof Active CA2873259C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1208548.6A GB201208548D0 (en) 2012-05-15 2012-05-15 Compound and method
GB1208548.6 2012-05-15
PCT/EP2013/059968 WO2013189663A1 (en) 2012-05-15 2013-05-14 Conjugate of a photosensitiser and chitosan and uses thereof

Publications (2)

Publication Number Publication Date
CA2873259A1 CA2873259A1 (en) 2013-12-27
CA2873259C true CA2873259C (en) 2021-08-03

Family

ID=46458880

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2873259A Active CA2873259C (en) 2012-05-15 2013-05-14 Conjugate of a photosensitiser and chitosan and uses thereof

Country Status (23)

Country Link
US (1) US9901636B2 (https=)
EP (1) EP2849791B1 (https=)
JP (1) JP6456284B2 (https=)
KR (2) KR102269861B1 (https=)
CN (1) CN104780941B (https=)
AU (1) AU2013279748B2 (https=)
BR (1) BR112014028315B1 (https=)
CA (1) CA2873259C (https=)
DK (1) DK2849791T3 (https=)
ES (1) ES2682762T3 (https=)
GB (1) GB201208548D0 (https=)
HR (1) HRP20181276T1 (https=)
HU (1) HUE039725T2 (https=)
IN (1) IN2014DN09418A (https=)
MX (1) MX362237B (https=)
NZ (1) NZ630582A (https=)
PL (1) PL2849791T3 (https=)
PT (1) PT2849791T (https=)
RU (1) RU2675830C2 (https=)
SG (1) SG11201407603YA (https=)
SI (1) SI2849791T1 (https=)
WO (1) WO2013189663A1 (https=)
ZA (1) ZA201408406B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
AU2014390262B2 (en) 2014-04-11 2020-11-26 Pci Biotech As Method of treating melanoma
EP3185901B1 (en) 2014-08-28 2023-10-04 PCI Biotech AS Compound and method
CN104650259A (zh) * 2015-01-23 2015-05-27 广西大学 一种纳米孔壳聚糖四(4-磺酸基苯基)金属卟啉微球及其制备方法和使用方法
GB201503776D0 (en) 2015-03-05 2015-04-22 Pci Biotech As Compound and method
GB201511159D0 (en) 2015-06-24 2015-08-05 Univ Nottingham Controlled cell delivery vehicle and treatment of tumours
WO2017162918A1 (en) 2016-03-22 2017-09-28 Åbo Akademi University Polysaccharide derivatives as optical brightening agents
KR20190013289A (ko) * 2017-08-01 2019-02-11 순천대학교 산학협력단 수용성 키토산을 포함하는 나노광증감제
GB201801169D0 (en) 2018-01-24 2018-03-07 Pci Biotech As Method
CN108892743A (zh) * 2018-05-28 2018-11-27 南京工业大学 用于光动力抗菌的纳米光敏剂,其制备方法及应用
GB202101726D0 (en) 2021-02-08 2021-03-24 Pci Biotech As Method
CN115399328B (zh) * 2021-05-27 2024-03-22 中国科学院化学研究所 一种多糖基杀菌材料及其制备方法和应用
GB202115451D0 (en) 2021-10-27 2021-12-08 Pci Biotech As Method
CN117285662A (zh) * 2022-06-15 2023-12-26 南京仁为医药科技有限公司 一种壳聚糖双吡啶季铵盐及其制备方法
GB202301312D0 (en) 2023-01-30 2023-03-15 Pci Biotech As Method and product

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
GB0018527D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Composition
JP2002241307A (ja) * 2001-02-19 2002-08-28 Yasuhiko Tabata 光増感剤を含有する超音波治療用活性酸素発生剤
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
GB0415663D0 (en) 2004-07-13 2004-08-18 Psimei Pharmaceuticals Plc Compound
WO2007023398A2 (en) 2005-05-16 2007-03-01 Universite De Geneve Compounds for photochemotherapy
JP4287411B2 (ja) * 2005-07-01 2009-07-01 株式会社東芝 仮想メモリシステムおよび仮想記憶方法
CN101024087A (zh) * 2007-03-28 2007-08-29 长沙理工大学 壳聚糖-多肽-卟啉纳米药物载体及其制备和应用
KR101035269B1 (ko) 2007-04-23 2011-05-26 한국과학기술연구원 고분자 유도체-광감작제 복합체를 이용한 새로운 광역학치료제
KR20090047872A (ko) 2007-11-08 2009-05-13 인제대학교 산학협력단 신규 카보하이드레이트 복합 클로린 화합물 및 이의제조방법
WO2009077908A1 (en) 2007-12-14 2009-06-25 University Of Lausanne Colloidal particle comprising multivalent cyclic anions
KR101076717B1 (ko) 2008-11-07 2011-10-26 재단법인대구경북과학기술원 광역학 치료용 나노구조체 및 그 제조방법
US20100129432A1 (en) 2008-11-25 2010-05-27 Taipei Medical University Microorganism-killing combination
WO2010126179A1 (ko) 2009-04-29 2010-11-04 다이아텍코리아 주식회사 클로린 e6-엽산 결합 화합물 및 키토산을 함유하는 암 치료용 약학적 조성물
KR100918811B1 (ko) 2009-04-29 2009-09-25 다이아텍코리아 주식회사 클로린 e6-엽산 결합 화합물 및 키토산을 함유하는 암 치료용 약학적 조성물
EP2440247B1 (en) 2009-06-12 2017-03-08 Erasmus University Medical Center Rotterdam Targeted nano-photomedicines for photodynamic therapy of cancer
GB0914287D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Compositions
KR101228106B1 (ko) 2010-01-21 2013-02-01 광주과학기술원 피부투과도, 세포유입 및 종양전달성이 증가된 나노운반체
KR101250150B1 (ko) * 2010-10-29 2013-04-04 가톨릭대학교 산학협력단 광역학치료를 위한 고분자-광응답제 접합체 및 이의 제조방법

Also Published As

Publication number Publication date
ZA201408406B (en) 2016-02-24
NZ630582A (en) 2017-02-24
MX2014013516A (es) 2015-11-13
JP2015516496A (ja) 2015-06-11
KR20200085380A (ko) 2020-07-14
CN104780941A (zh) 2015-07-15
WO2013189663A1 (en) 2013-12-27
KR20150013803A (ko) 2015-02-05
BR112014028315A2 (pt) 2017-10-24
PT2849791T (pt) 2018-10-04
CN104780941B (zh) 2019-01-15
HK1203850A1 (en) 2015-11-06
KR102269861B1 (ko) 2021-06-28
RU2014150569A (ru) 2016-07-10
EP2849791B1 (en) 2018-07-04
US20150202293A1 (en) 2015-07-23
GB201208548D0 (en) 2012-06-27
HUE039725T2 (hu) 2019-01-28
HRP20181276T1 (hr) 2018-11-16
RU2675830C2 (ru) 2018-12-25
SI2849791T1 (sl) 2018-10-30
AU2013279748B2 (en) 2018-08-02
PL2849791T3 (pl) 2019-03-29
AU2013279748A1 (en) 2014-11-20
ES2682762T3 (es) 2018-09-21
EP2849791A1 (en) 2015-03-25
JP6456284B2 (ja) 2019-01-23
MX362237B (es) 2019-01-09
US9901636B2 (en) 2018-02-27
IN2014DN09418A (https=) 2015-07-17
SG11201407603YA (en) 2014-12-30
DK2849791T3 (en) 2018-08-13
CA2873259A1 (en) 2013-12-27
BR112014028315B1 (pt) 2022-02-22

Similar Documents

Publication Publication Date Title
CA2873259C (en) Conjugate of a photosensitiser and chitosan and uses thereof
CA2457856C (en) Sulphonated meso-tetraphenyl chlorins and their use as therapeutic agents
Maruani et al. Site-selective multi-porphyrin attachment enables the formation of a next-generation antibody-based photodynamic therapeutic
US9026203B2 (en) Photosensitizing compositions
CN105940005A (zh) 二氮杂环庚烷衍生物及其用途
JP2020526519A (ja) 分枝多官能性マクロモノマーおよび関連ポリマーならびにそれらの使用
JP2015155442A (ja) 化合物及び生物学的材料並びにそれらの使用
CN105939607A (zh) 二氢蝶啶酮衍生物及其用途
KR20220085791A (ko) 브러시 전구약물 및 그의 용도
Gaware et al. Endosome targeting meso-tetraphenylchlorin–chitosan nanoconjugates for photochemical internalization
Wu et al. Near-infrared light-initiated upconversion nanoplatform with tumor microenvironment responsiveness for improved photodynamic therapy
Krylova et al. Developing chlorin/arylaminoquinazoline conjugates with nanomolar activity for targeted photodynamic therapy: design, synthesis, SAR, and biological evaluation
Tang et al. A integrated molecule based on ferritin nanoplatforms for inducing tumor ferroptosis with the synergistic photo/chemodynamic treatment
Yin et al. Formulation and evaluation of lipidized imiquimod as an effective adjuvant
US10561730B2 (en) Plant virus particles for delivery of photosensitive agents
US20250304545A1 (en) Water-soluble heterocyclyl polymethine chromophores
HK1203850B (en) Conjugate of a photosensitiser and chitosan and uses thereof
Sun et al. A hypoxia-responsive prodrug for specific drug release and synergistic chemo-photodynamic cancer therapy
Çavdarbasha Synthesis of in vitro activatable silicon phthalocyanines
AU2002313562C1 (en) Compound
Mion Towards new photodynamic therapy agents: synthesis, biological evaluation and targeting to tumor cells
Fernandez-Megia Synthesis of multi-functional dendrimers for targeted delivery of nucleic acids
AU2002313562A1 (en) Compound

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180511

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251009